Vertex Pharmaceuticals | VRTX - SCHULD

Aktienkurs
430.93
Täglich Wechseln
-3.37 -0.78%
Monatlich
-6.50%
Jährlich
-8.77%
Q2 Prognose
425.50




SCHULD Veränderung Datum
AbbVie USD 1000K 70.48B 2025-09
Acadia Pharmaceuticals USD 54.81M 1.48M 2025-09
Agios Pharmaceuticals USD 44.52M 4.24M 2025-09
Alnylam Pharmaceuticals USD 1.31B 11.39M 2025-09
Amgen USD 54.59B 1.62B 2025-09
Arrowhead Research USD 366.28M 13.25M 2025-09
Biogen USD 6.29B 1.7M 2025-12
BioMarin Pharmaceutical USD 604.24M 375K 2025-09
Bristol-Myers Squibb USD 51.04B 112M 2025-09
Gilead Sciences USD 24.94B 5M 2025-09
Incyte USD 40.41M 855K 2025-12
Insmed USD 727.89M 163.33M 2025-12
Ionis Pharmaceuticals USD 2.33B 1.1B 2025-12
J&J USD 45.8B 4.97B 2025-09
Merck USD 41.37B 5.97B 2025-09
Moderna USD 734M 7M 2025-09
Neurocrine Biosciences USD 428.4M 10.7M 2025-09
Novartis USD 32.64B 1.37B 2025-06
Pfizer USD 60.85B 78M 2025-09
PTC Therapeutics USD 286.32M 306K 2025-09
Puma Biotechnology USD 89.06M 55.07M 2024-06
Regeneron Pharmaceuticals USD 2.71B 400K 2025-09
Roche Holding CHF 33.03B 1.41B 2025-06
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 21.76B 530M 2025-09
Sarepta Therapeutics USD 1.25B 103.69M 2025-09
Ultragenyx Pharmaceutical USD 33.83M 2.46M 2025-09
United Therapeutics USD 200M 100M 2025-03
Vertex Pharmaceuticals USD 1.83B 307.4M 2025-09